Rupinder Kaur
Greensboro, NCNPI 1740213982
Payments from drug & device makers
Across 997 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$987
- Alkermes, Inc.$931
- Teva Pharmaceuticals USA, Inc.$669
- plus $4K from 31 others
What the payments were for
- Food & beverage$12,53499%
- Education$1151%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$148
- CAPLYTA$127
- Dyanavel XR$123
- Quillivant$123
- Quillichew ER$123
- SPRAVATO$107
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 38 | $193,609 |
| IngrezzaValbenazine Tosylate | 22 | $191,159 |
| CaplytaLumateperone Tosylate | 106 | $176,237 |
| AustedoDeutetrabenazine | 28 | $173,820 |
| TrintellixVortioxetine Hydrobromide | 238 | $142,262 |
| VraylarCariprazine Hcl | 80 | $126,237 |
| SpravatoEsketamine Hcl | 76 | $116,655 |
| AuvelityDextromethorphan Hbr/Bupropion | 79 | $84,521 |
| RexultiBrexpiprazole | 55 | $83,629 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 1,173 | $52,407 |
| BelsomraSuvorexant | 57 | $29,628 |
| LatudaLurasidone Hcl | 15 | $26,770 |
| Vilazodone Hcl | 195 | $21,542 |
| Lurasidone Hcl | 124 | $18,031 |
| VyvanseLisdexamfetamine Dimesylate | 44 | $16,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $669 | $367,43066 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $453 | $191,15922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $987 | $176,237106 claims |
| AbbVieVraylar, Savella, Fetzima, Viibryd | $2,567 | $162,309164 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,054 | $158,435282 claims |
| Johnson & JohnsonSpravato | $1,968 | $116,65576 claims |
| Axsome Therapeutics, Inc.Auvelity | $278 | $84,52179 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $637 | $83,62955 claims |
| MerckBelsomra | $340 | $29,62857 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $195 | $26,77015 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $20 | $9,88116 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $119 | $7,85011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.